利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

78 条记录 (耗时 0.056 秒)

    14815, a human kinase family member and uses therefor
    62.
    发明申请
    14815, a human kinase family member and uses therefor 失效
    14815，一种人激酶家族成员，并用于此

    公开(公告)号：US20050118608A1

    公开(公告)日：2005-06-02

    申请号：US10831011

    申请日：2004-04-23

    申请人： Rachel Meyers

    发明人： Rachel Meyers

    IPC分类号： C12N9/12 ,  C12Q1/68 ,  C07H21/04

    CPC分类号： C12N9/1205

    摘要： The invention provides isolated nucleic acids molecules, designated 14815 nucleic acid molecules, which encode novel kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14815 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14815 gene has been introduced or disrupted. The invention still further provides isolated 14815 proteins, fusion proteins, antigenic peptides and anti-14815 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

    摘要翻译： 本发明提供编码新型激酶家族成员的分离的核酸分子，命名为14815个核酸分子。 本发明还提供了反义核酸分子，含有14815个核酸分子的重组表达载体，已经引入了表达载体的宿主细胞，以及引入或破坏14815基因的非人转基因动物。 本发明还进一步提供了分离的14815蛋白，融合蛋白，抗原肽和抗14815抗体。 还提供了利用本发明组合物的诊断和治疗方法。

    32142,21481,25964,21686, novel human dehydrogenase molecules and uses therefor
    63.
    发明授权
    32142,21481,25964,21686, novel human dehydrogenase molecules and uses therefor 有权
    32142,21481,25964,21686，新型人脱氢酶分子及其用途

    公开(公告)号：US06511834B1

    公开(公告)日：2003-01-28

    申请号：US09634955

    申请日：2000-08-08

    申请人： Rachel Meyers ,  William James Cook

    发明人： Rachel Meyers ,  William James Cook

    IPC分类号： C12N904

    CPC分类号： C12N9/0004 ,  C07K2319/00

    摘要： The invention provides isolated nucleic acids molecules, designated DHDR nucleic acid molecules, which encode novel DHDR-related dehydrogenase molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing DHDR nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DHDR gene has been introduced or disrupted. The invention still further provides isolated DHDR proteins, fusion proteins, antigenic peptides and anti-DHDR antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

    摘要翻译： 本发明提供编码新型DHDR相关脱氢酶分子的分离的核酸分子，命名为DHDR核酸分子。 本发明还提供了反义核酸分子，含有DHDR核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，以及DHDR基因导入或破坏的非人类转基因动物。 本发明还进一步提供了分离的DHDR蛋白，融合蛋白，抗原肽和抗DHDR抗体。 还提供了利用本发明组合物的诊断方法。

    RNAi modulation of RSV and therapeutic uses thereof
    65.
    发明授权
    RNAi modulation of RSV and therapeutic uses thereof 有权
    RSV的RNAi调节及其治疗用途

    公开(公告)号：US07981869B2

    公开(公告)日：2011-07-19

    申请号：US12326867

    申请日：2008-12-02

    申请人： Rachel Meyers

    发明人： Rachel Meyers

    IPC分类号： C12N15/11 ,  C07H21/02 ,  C07H21/04

    CPC分类号： C12N15/1131 ,  A61K9/0078 ,  A61K31/713 ,  A61M11/06 ,  A61M15/00 ,  A61M16/14 ,  A61M2202/04 ,  A61M2202/064 ,  C12N2310/14 ,  C12N2320/31 ,  C12N2320/32

    摘要： The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses.

    摘要翻译： 本发明基于体内证据，可以通过鼻内施用iRNA试剂以及通过肠胃外给药这种试剂来抑制RSV。 此外，显示可以同时治疗多于一种的病毒来实现有效的病毒降低。 基于这些发现，本发明提供了可用于减少受试者例如哺乳动物（例如人）中的RSV mRNA水平，RSV蛋白水平和病毒滴度的一般和特定组合物和方法。 这些发现可以应用于其他呼吸道病毒。

    RNAi Modulation of RSV and Therapeutic Uses Thereof
    67.
    发明申请
    RNAi Modulation of RSV and Therapeutic Uses Thereof 有权
    RSV的RNAi调控及其治疗用途

    公开(公告)号：US20090233984A1

    公开(公告)日：2009-09-17

    申请号：US12326867

    申请日：2008-12-02

    申请人： Rachel Meyers

    发明人： Rachel Meyers

    IPC分类号： A61K31/7105

    CPC分类号： C12N15/1131 ,  A61K9/0078 ,  A61K31/713 ,  A61M11/06 ,  A61M15/00 ,  A61M16/14 ,  A61M2202/04 ,  A61M2202/064 ,  C12N2310/14 ,  C12N2320/31 ,  C12N2320/32

    摘要： The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses.

    摘要翻译： 本发明基于体内证据，可以通过鼻内施用iRNA试剂以及通过肠胃外给药这种试剂来抑制RSV。 此外，显示可以同时治疗多于一种的病毒来实现有效的病毒降低。 基于这些发现，本发明提供了可用于减少受试者例如哺乳动物（例如人）中的RSV mRNA水平，RSV蛋白水平和病毒滴度的一般和特定组合物和方法。 这些发现可以应用于其他呼吸道病毒。

    RNAi modulation of RSV and therapeutic uses thereof
    68.
    发明授权
    RNAi modulation of RSV and therapeutic uses thereof 失效
    RSV的RNAi调节及其治疗用途

    公开(公告)号：US07507809B2

    公开(公告)日：2009-03-24

    申请号：US11326956

    申请日：2006-01-06

    申请人： Rachel Meyers

    发明人： Rachel Meyers

    IPC分类号： C07H21/04

    CPC分类号： C12N15/1131 ,  A61K9/0078 ,  A61K31/713 ,  A61M11/06 ,  A61M15/00 ,  A61M16/14 ,  A61M2202/04 ,  A61M2202/064 ,  C12N2310/14 ,  C12N2320/31 ,  C12N2320/32

    摘要： The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses.

    摘要翻译： 本发明基于体内证据，可以通过鼻内施用iRNA试剂以及通过肠胃外给药这种试剂来抑制RSV。 此外，显示可以同时治疗多于一种的病毒来实现有效的病毒降低。 基于这些发现，本发明提供了可用于减少受试者例如哺乳动物（例如人）中的RSV mRNA水平，RSV蛋白水平和病毒滴度的一般和特定组合物和方法。 这些发现可以应用于其他呼吸道病毒。

    12832, a novel human kinase-like molecule and uses thereof
    70.
    发明授权
    12832, a novel human kinase-like molecule and uses thereof 失效
    12832，一种新的人激酶样分子及其用途

    公开(公告)号：US07214374B2

    公开(公告)日：2007-05-08

    申请号：US10682739

    申请日：2003-10-09

    申请人： Rachel Meyers ,  Martin R. Hodge ,  Mark Williamson

    发明人： Rachel Meyers ,  Martin R. Hodge ,  Mark Williamson

    IPC分类号： A61K39/00 ,  G01N33/53

    CPC分类号： C12N9/1205 ,  A61K38/00 ,  A61K48/00 ,  C07K16/40 ,  C12Q1/6886 ,  C12Q2600/136

    摘要： Novel human kinase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase-like proteins, the invention further provides isolated kinase-like fusion proteins, antigenic peptides, and anti-kinase-like antibodies. The invention also provides kinase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

    摘要翻译： 公开了新的人激酶样多肽，蛋白质和核酸分子。 除了分离的全长激酶样蛋白之外，本发明还提供了分离的激酶样融合蛋白，抗原肽和抗激酶样抗体。 本发明还提供激酶样核酸分子，含有本发明的核酸分子的重组表达载体，已经引入了表达载体的宿主细胞和其中已经引入或破坏了类似激酶的基因的非人类转基因动物 。 还提供了利用本发明组合物的诊断，筛选和治疗方法。